Articles

Upon retiring, cash out your 401(k) and buy a bond “ladder” of Treasury inflation-protected securities.

Andrew Thrasher, founder of Thrasher Analytics, said the stock market has been low on sellers who may be starting to return.

Sarepta Therapeutics shares were lower in premarket trading on Tuesday, as the drugmaker relented to a Food and Drug Administration request to halt shipments of a gene therapy.

“I took out a $250,000 policy for a 10-year term. At the time, the payments were $200 per month.”

Even any good news about the Austin robotaxi rides may not be enough to lift the stock, which has lost about a quarter of its value since a record high in December.

For all the talk of artificial intelligence being in a bubble, Bank of America’s derivatives strategists say there’s one missing element.

Olympic legend Simone Biles is no doubt hoping that good things come to those who wait—particularly when that wait has stretched on for more than two years.

AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a move hailed by the Trump administration — though much of what it is announcing it’s already announced before.

Despite expectations for a mixed second quarter, some analysts are staying confident on IBM’s software segment

In the span of about a week, Opendoor Technologies Inc. has gone from a struggling former pandemic-era darling to the talk of the U.S. equity market.

A weaker dollar, the global AI race and plans for ramped-up government spending abroad are all reasons why global equities can shine in the months and years ahead.

The estimate comes from the nonpartisan Congressional Budget Office, which President Trump and Republicans have attacked.